Sign In
Buy PCVX
$51.96
-0.150 (-0.288%)
At Close: Jun 23, 2026
Vaxcyte to Present at the Jefferies Healthcare Conference
04:05pm, Thursday, 01'st Jun 2023
SAN CARLOS, Calif., June 01, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequ
Wall Street Analysts Think Vaxcyte, Inc. (PCVX) Could Surge 33.33%: Read This Before Placing a Bet
11:05am, Monday, 29'th May 2023
The average of price targets set by Wall Street analysts indicates a potential upside of 33.3% in Vaxcyte, Inc. (PCVX). While the effectiveness of this highly sought-after metric is questionable, the
Vaxcyte: Positive Phase 2 Results Elevate Confidence In VAX-24's Potential
08:20am, Wednesday, 17'th May 2023
Vaxcyte is emerging as a leader in vaccine innovation, leveraging high-fidelity vaccines to combat bacterial diseases. The company's lead candidate, VAX-24, demonstrated robust immune responses and a
Vaxcyte to Present at the BofA Securities 2023 Health Care Conference
04:05pm, Wednesday, 03'rd May 2023
SAN CARLOS, Calif., May 03, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the conseque
Where Is The Current Bull Market? Scan Of Stocks Gaining Over 20% Over The Past Week Almost Exclusively Yields Biotech Names
08:07am, Thursday, 20'th Apr 2023
Where is the current bull market? All indications would be that it's in biotech!
Vaxcyte (PCVX) Up on Pneumococcal Conjugate Vaccine Data
02:28pm, Tuesday, 18'th Apr 2023
Vaxcyte (PCVX) announces positive results from the mid-stage study of its 24-Valent pneumococcal conjugate vaccine candidate, VAX-24, in adults aged 65 and older.
Still 50% Upside To Go, Wall Street Is Getting Vaxcyte Right
08:36am, Tuesday, 18'th Apr 2023
When SVB Securities analyst David Risinger reiterated his bullish opinion on Vaxcyte, Inc. (NASDAQ: PCVX) last week, few investors noticed. The stock barely budged.
SAN CARLOS, Calif., April 16, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the conseq
Vaxcyte, Inc. (PCVX) Q4 2022 Earnings Call Transcript
10:03pm, Monday, 27'th Feb 2023
Vaxcyte, Inc. (NASDAQ:PCVX ) Q4 2022 Earnings Conference Call February 27, 2023 4:30 PM ET Company Participants Andrew Guggenhime - President and Chief Financial Officer Grant Pickering - Chief Execut
Vaxcyte to Report Fourth Quarter and Full Year 2022 Financial Results on February 27, 2023
04:05pm, Thursday, 16'th Feb 2023
SAN CARLOS, Calif., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequ
Vaxcyte to Present at the SVB Securities Global Biopharma Conference
04:05pm, Tuesday, 07'th Feb 2023
SAN CARLOS, Calif., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequ
5 Best and Worst Performing Mid-Cap Stocks in Q4 2022
10:53pm, Thursday, 19'th Jan 2023
Mid-cap stocks are proving to be an attractive investment option over the past few years.
These Were The Five Best And Worst Performing Mid-Cap Stocks In October 2022
08:22pm, Tuesday, 15'th Nov 2022
Mid-cap companies lie in between the slower growth large-cap stocks and the faster-growth small-cap businesses.
Vaxcyte Has A Bright Future Ahead
03:01pm, Wednesday, 02'nd Nov 2022
Not everything is negative in this bearish market. The healthcare sector is home to stocks with rosy prospects.
Why Investors Are Suddenly Excited About Vaxcyte
10:46am, Monday, 31'st Oct 2022
Vaxcyte, Inc. is a small cap biotech company that catapulted back to mid-cap land with a stunning 110% surge — and may not be done yet.
